CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.
Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *
In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).
Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.
* Required

Your name *
First Last
Luca Camerini

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
Institute of Communication

Your e-mail address *
abc@gmail.com
luca.camerini@usi.ch

Title of your manuscript *
Provide the (draft) title of your manuscript.

**Article Preparation Status/Stage** *
At which stage in your article preparation are you currently (at the time you fill in this form)
- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Other:

**Journal** *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")
- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- Other:

**Manuscript tracking number** *
If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)
- no ms number (yet) / not (yet) submitted to / published in JMIR
- Other: ms #1953

**TITLE AND ABSTRACT**

1a) **TITLE:** Identification as a randomized trial in the title

1a) **Does your paper address CONSORT item 1a?** *
I.e. does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

yes

Other: The experiment was random.

1a-i) Identify the mode of delivery in the title
Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "online" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iPhone"), especially if the application runs on different platforms.

1 2 3 4 5

subitem not at all important essential

Does your paper address subitem 1a-i? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. However, the mode of delivery is clearly indicated in the manuscript.
Quote: "In order to test these hypotheses, a web-based eHealth intervention for patients affected by FMS was developed".

1a-ii) Non-web-based components or important co-interventions in title
Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

1 2 3 4 5

subitem not at all important essential

Does your paper address subitem 1a-ii?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. Non-web-based components were not included in the study.
1a-iii) Primary condition or target group in the title
Mention primary condition or target group in the title, if any (e.g., “for children with Type I Diabetes”)
Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

Does your paper address subitem 1a-iii? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. The condition is Fibromyalgia and it’s clearly stated in the title.
Quote: “Effects of Functional Interactivity on Fibromyalgia Patients’ Knowledge, Empowerment, and Health Outcomes...”

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions
NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionality/components of the intervention and comparator in the METHODS section of the ABSTRACT
Mention key features/functionality/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

Does your paper address subitem 1b-i? *
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
YES, at least partly.
Quote: "This study relies on a pre-post test experimental design where three different versions of the eHealth intervention were manipulated. The three conditions implemented different functions (e.g., information library, web forum, testimonials, chat room). A total of 165 patients were recruited through patients’ associations and randomized into three experimental groups, corresponding to different levels of functional interactivity."

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT
Clarify the level of human involvement in the abstract, e.g., use phrases like “fully automated” vs. "therapist/nurse/care provider/physician-assisted” (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

Does your paper address subitem 1b-ii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No human involvement occurred.

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT
Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use “blinded” or “unblinded” to indicated the level of blinding instead of “open”, as "open" in web-based trials usually refers to “open access” (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

Does your paper address subitem 1b-iii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
YES.
Quote: "A total of 165 patients were recruited through patients’ associations and randomized into three experimental groups, corresponding to different levels of functional interactivity."

1b-iv) RESULTS section in abstract must contain use data
Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 1b-iv?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. Usage is discussed in the manuscript.

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials
Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 1b-v?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
YES, partly.
Quote: "The main result was that functional interactivity was not found to have an impact on empowerment dimensions nor direct observable effects on knowledge. In turn, knowledge positively impacted health outcomes (b = -1.2, P = .02) and so did the empowerment dimensions of meaning (b = -.49, P = .000) and impact (b = -.25, P = .000)."

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution
Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

1 2 3 4 5

subitem not at all important essential

Does your paper address subitem 2a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES, partly. We discussed the rationale for developing the intervention and the problem at the origin of the study. However, we described the intervention in the Method section.
Quote: "There is a need not only to know whether eHealth interventions work, but also to understand how they achieve their effectiveness."
Quote: "we hypothesize that the availability of interactive functions in eHealth interventions positively affects users' knowledge and their empowerment, and further that knowledge and empowerment positively affect health outcomes."

2a-ii) Scientific background, rationale: What is known about the (type of) system
Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5

subitem not at all important essential
Does your paper address subitem 2a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms., or briefly explain why the item is not applicable/relevant for your study and empowerment on the other are plausible to assume, for it takes knowledge and literacy to benefit from eHealth applications, and bringing them up in medical consultation gives a more active role to patients, who thus claim autonomy. Knowledge and empowerment can also be assumed to be affected by eHealth interventions and their qualities. In a sense, such links are obvious to assume, but they are largely unexplored by research, and therefore not established at all. Our research aims at contributing to this area, resting on the assumption that eHealth requires and fosters patient autonomy."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms., or briefly explain why the item is not applicable/relevant for your study

NO.

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms., or briefly explain why the item is not applicable/relevant for your study
patients by phone and e-mail. Patients were introduced to the study and asked to register to the ONESELF website. After the registration they had to accept an Informed Consent statement and finally complete a first questionnaire. After the questionnaire was completed, the patients could access the website and start the navigation. After five months of navigation, a second questionnaire was presented and completed. A maximum of three reminders/prompts were used to maximize response rate. By the end of the recruitment process, a total of 165 patients agreed to participate to the experiment "

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No changes in the intervention were made.

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) [5-iii] and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No changes made.
### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES.

Quote: "In order to be eligible for the study, patients had to meet a set of inclusion criteria, namely a) possess a fluent knowledge of Italian, b) have access to the Internet, c) be confident on how to use a computer, and d) have received a diagnosis of FMS from a doctor."

#### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Does your paper address subitem 4a-i? 
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES.

Quote: "In order to be eligible for the study, patients had to meet a set of inclusion criteria, namely ... c) be confident on how to use a computer".

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Does your paper address subitem 4a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
describing the aims of the study, together with a contact form. If interested in the study, patients had to send the form back to the research team, filled with contact details. The research team contacted the patients by phone and e-mail. Patients were introduced to the study and asked to register to the ONESELF website. After the registration they had to accept an Informed Consent statement and finally complete a first questionnaire. After the questionnaire was completed, the patients could access the website and start the navigation.

4a-iii) Information giving during recruitment
Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

<table>
<thead>
<tr>
<th>subitem not at all important</th>
<th>essential</th>
</tr>
</thead>
</table>

Does your paper address subitem 4a-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. See above.
Additional quote: "After five months of navigation, a second questionnaire was presented and completed. A maximum of three reminders/prompt were used to maximize response rate."

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES.
Quote: "Each construct of the eHealth intervention effect model was translated into operational measures. The assessments were conducted using standardized self-assessed online questionnaires. The questionnaires were pre-tested for face and content validity with two focus groups, with four health professionals and four patients respectively."

4b-i) Report if outcomes were (self-)assessed through online questionnaires
Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.
Does your paper address subitem 4b-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Empowerment: Empowerment was measured according to the scale proposed by Spreitzer [75], but adapted to the FMS domain. The measure reflects the multidimensionality of the construct of empowerment, which is a combination of meaning, competence, self-determination, and impact. Each one of the subdimensions is treated as a latent construct with three observed indicators. Each indicator was measured on a 7-point Likert-scale.

Health outcomes: Health outcomes were measured with the Fibromyalgia Impact Questionnaire (FIQ) [60, 61] in its Italian version [76]. The FIQ is a validated questionnaire that consists of 20 indicators to assess patients' disability to carry out everyday activities, patients' intensity of pain, and the interference of FMS with patients' sleep and emotional state. The FIQ provides a single score ranging from 0 to 100 where a higher score indicates a greater impact of FMS on the patient. For this reason, it should be considered a measure of negative health outcomes. According to Bennett [61] the average FMS patients scores about 50. Because of the high theoretical variance of this measure compared to the others, the FIQ raw score was transformed on a 0-10 scale and used as a single manifest indicator throughout the analyses.

---

4b-ii) Report how institutional affiliations are displayed
Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

Does your paper address subitem 4b-ii? 
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

NO. No important or prestigious institutions were involved in the study.

---

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a “Conflict of interest” section or mentioned elsewhere in the manuscript).

---
Does your paper address subitem 5-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

YES. We declare that the intervention was developed by the researcher at our University.

5-ii) Describe the history/development process
Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

<table>
<thead>
<tr>
<th>Subitem</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not at all important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>essential</td>
</tr>
</tbody>
</table>

Does your paper address subitem 5-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Quote: "In order to test these hypotheses, a web-based eHealth intervention for patients affected by FMS was developed. This application, called ONESELF, was developed in collaboration with health professionals (rheumatologists, physiotherapists, general practitioners), and it is fully compliant with the Health On the Net Foundation guidelines (HON-Code)."

Quote: "A more detailed description of the design of the application is presented elsewhere [68, 69], together with qualitative insights on the user experience with the system, which was generally considered useful, usable, and comprehensible. Since its first release in June 2008, more than 600 FMS patients mostly from Switzerland and Italy (the site language being Italian) have registered to ONESELF."

5-iii) Revisions and updating
Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

<table>
<thead>
<tr>
<th>Subitem</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not at all important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>essential</td>
</tr>
</tbody>
</table>

Does your paper address subitem 5-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
NO. Not applicable because the intervention had no revisions nor updatings other than the actual usage by the patients (e.g. forum posts or chat room discussions).

5-iv) Quality assurance methods
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

1 2 3 4 5
subitem not at all important essential

Does your paper address subitem 5-iv?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Quote: "This application, called ONESELF, was developed in collaboration with health professionals (rheumatologists, physiotherapists, general practitioners), and it is fully compliant with the Health On the Net Foundation guidelines (HON-Code). The HON-Code prescribes guidelines on the quality of the contents and the overall usability of the application. Indeed, these intrinsic factors can play a decisive role in the ultimate effects of an online intervention, and compliance with these guidelines helps tempering - and to some extent ruling out - potential biases caused by usability issues."

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used
Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

1 2 3 4 5
subitem not at all important essential

Does your paper address subitem 5-v?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Quote: "A virtual gymnasium provided patients with tailored multimedia contents on several physical exercises that constitute the wider part of the non-pharmacological treatment of FMS. Eventually, a section on testimonies, where patients could post their stories and read stories of other people suffering from the same health condition, enhanced the dimension of social support. Synchronous interaction was designed and implemented via an online forum and a chat. Patients used these tools to communicate with the physicians and among themselves."
5-vi) Digital preservation
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

Does your paper address subitem 5-vi?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. The application is and will continue to be accessible (but only in Italian).

5-vii) Access
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

Does your paper address subitem 5-vii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. Quote: “This study relies on a pre-post test experimental design. Patients were contacted by two means: a list of patients that are members of the Associazione Fibromialgici Svizzeri Sezione Ticino (Ticino Fibromyalgia Patients Association) and patients visiting health professionals (rheumatologists, physiotherapists). Health professionals were involved in the recruitment to assure that patients received a diagnosis of FMS from a doctor. In order to be eligible for the study, patients had to meet a set of inclusion criteria, namely a) possess a fluent knowledge of Italian, b) have access to the Internet, c) be confident on how to use a computer, and d) have received a diagnosis of FMS from a doctor. Every patient who matched these criteria was given a letter, briefly describing the aims of the study, together with a contact form. If interested in the study, patients had to send the form back to the research team, filled with contact details. The research team contacted the patients by phone and e-mail. Patients were introduced to the study and asked to register to the ONESELF website. After the registration they had to accept an Informed Consent statement and finally complete a first self-assessed online questionnaire. After the questionnaire was completed, the patients could access the website and start the navigation. After five months of navigation, a second questionnaire was presented and completed. A maximum of three reminders/prompts were used to maximize response rate. By the end of the recruitment process, a total of 165 patients agreed to participate to the experiment (Figure 2).”

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework
Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback” [6]. This also includes a description of communication delivery channels and – if
Does your paper address subitem 5-viii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Interactivity. While the library, the virtual gymnasium, and the testimonials did not allow any input from the user other than traditional hyper-textual navigation, the web forum and the chat room enabled synchronous and asynchronous interactions. Although this kind of approach has been criticized for being too generic [15], it is useful to capture the contribution of different enabling functions [70], and it was adopted in other studies on interactivity as well (e.g. [64, 71-73]).

5-ix) Describe use parameters
Describe use parameters (e.g., intended “doses” and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

Usage of the application has no strong influence on the relationships investigated in the present analysis. It must be acknowledged, however, that the scant usage of the system may underestimate the results of the present analysis. Under the assumption that a more frequent usage should lead to larger effects, the differential impact of some features that were seldom used (i.e. the chat room) might stay covered. We accounted for this in the power and effect size considerations that are detailed in Multimedia Appendix 1.

5-x) Clarify the level of human involvement
Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as “type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered”. It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).
Does your paper address subitem 5-x?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No human involvement was necessary.

5-xi) Report any prompts/reminders used
Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5

subitem not at all important essential

Does your paper address subitem 5-xi? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES.
Quote: "A maximum of three reminders/prompts were used to maximize response rate."

5-xii) Describe any co-interventions (incl. training/support)
Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5

subitem not at all important essential

Does your paper address subitem 5-xii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
NO. Not applicable. We had no side or co-interventions.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms., or briefly explain why the item is not applicable/relevant for your study

YES. All measures were clearly described in a dedicated section.
Quote: "Measures
Each construct of the eHealth intervention effect model was translated into operational measures. The assessments were conducted using standardized self-assessed online questionnaires. The questionnaires were pre-tested for face and content validity with two focus groups, with four health professionals and four patients respectively. The measures used in the study were as follows:

Demographic characteristics: Demographics in the questionnaires included age, gender, and level of education. Age was used as an exogenous covariate in the model analysis, since it can discriminate other focal constructs (e.g. level of pain varies depending on age). Gender was measured but was not controlled for since the large majority of FMS patients are females and our sample reflected this datum [74].

Knowledge: Knowledge was measured following the approach of critical/integrative models of health literacy. Thus, knowledge was assessed with ten multiple-choice questions adapted from the website of Mayo Clinic related to FMS symptoms, etiology, treatments, and its management. Each answer was coded 1 when correct and 0 when incorrect. The final measure of knowledge was obtained by a mean score calculation of the 10 items, and its theoretical range goes from 0 (no correct response) to 1 (all correct responses).

Empowerment: Empowerment was measured according to the scale proposed by Spreitzer [75], but adapted to the FMS domain. The measure reflects the multidimensionality of the construct of empowerment, which is a combination of meaning, competence, self-determination, and impact. Each one of the sub-dimensions is treated as a latent construct with three observed indicators. Each indicator was measured on a 7-point Likert-scale.

Health outcomes: Health outcomes were measured with the Fibromyalgia Impact Questionnaire (FIQ) [60, 61] in its Italian version [76]. The FIQ is a validated questionnaire that consists of 20 indicators to assess patients’ disability to carry out everyday activities, patients’ intensity of pain, and the interference of FMS with patients’ sleep and emotional state. The FIQ provides a single score ranging from 0 to 100 where a higher score indicates a greater impact of FMS on the patient. For this reason, it should be considered a measure of negative health outcomes. According to Bennett [61] the average FMS patients scores about 50. Because of the high theoretical variance of this measure compared to the others, the FIQ raw score was transformed on a 0-10 scale and used as a single manifest indicator throughout the analyses.

Additional covariates: The number of years passed since the first diagnosis was measured as a single additional covariate. By doing so, it is possible to

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed
If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

Does your paper address subitem 6a-i?
Copy and paste relevant sections from manuscript text
NO. Questionnaire were checked for internal and external validity and valid scales were used whenever possible (as described in the Measurement paragraph of the ms). However, no specific check for online use was performed.

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored
Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.
Does your paper address subitem 6a-ii?
Copy and paste relevant sections from manuscript text

YES, partly. As we describe in the ms, we added a brief description of application usage and performed interaction analyses to check for possible moderation of this variable.
Quote: "As to the usage of the application, the mean number of visits as recorded by a log file analyzer was 13.27 (SD=26.68). The mean time spend on the website was 4.8 minutes per visit (SD=13.2). These figures suggest that the application was not used very often, but use patterns were similar across experimental conditions. Table 4 reports some usage data related to the main

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained
Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

subitem not at all important essential

Does your paper address subitem 6a-iii?
Copy and paste relevant sections from manuscript text

NO. We used no qualitative feedback in this analysis. The overall evaluation of the system (both quantitative and qualitative was described in previous work.
Quote: "A more detailed description of the design of the application is presented elsewhere [68, 69], together with qualitative insights on the user experience with the system, which was generally considered useful, usable, and comprehensible."

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No changes were made to the trial during the evaluation phase.
7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed.

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

YES. In Multimedia Appendix 1 we describe how power and sample size demands were taken into account.

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

NO. No interim analyses were made.
8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES, partly. We did not describe in detail the algorithm but we state that it is based on a random number generator.
Quote: "Patients were randomly assigned to one of the three versions and blinded to the others, using a computer utility that assigned them to a randomly selected experimental condition until the conditions were equally filled."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES.
Quote: "Patients were randomly assigned to one of the three versions and blinded to the others, using a computer utility that assigned them to a randomly selected experimental condition until the conditions were equally filled."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
NO. We did not include any specific algorithm description. The allocation sequence was random (no sequentially numbered containers).

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. Everything is described in a dedicated paragraph.
Quote: "Each patient who matched these criteria was given a letter, briefly describing the aims of the study, together with a contact form. If interested in the study, patients had to send the form back to the research team, filled with contact details. The research team contacted the patients by phone and e-mail. Patients were introduced to the study and asked to register to the ONESELF website. After the registration they had to accept an Informed Consent statement and finally complete a first questionnaire."

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't
Specify who was blinded, and who wasn’t. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

subitem not at all important essential

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
YES, partly. Participants were blinded to other conditions (web application versions) who could not be accessed without proper credentials. Quote: "Patients were randomly assigned to one of the three versions and blinded to the others, using a computer utility that assigned them to a randomly selected experimental condition until the conditions were equally filled."

11a-ii) Discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”
Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”.

12345
subitem not at all important essential

Does your paper address subitem 11a-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

YES.
Quote: "Patients were randomly assigned to one of the three versions and blinded to the others, using a computer utility that assigned them to a randomly selected experimental condition until the conditions were equally filled."

11b) If relevant, description of the similarity of interventions
(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

NO. Not applicable.
12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Quote: "The main analyses were conducted using Structural Equation Modeling (SEM) techniques [77]. AMOS® 18 was used for the analyses. Specifically, the effect of interactivity on knowledge, meaning, competence, self-determination, and impact was examined. Because of the relatively small sample size, it was not advisable to run a test on a model including the five focal dependent variables at the same time. Thus, an SEM model reflecting an ANCOVA for the analysis of change was implemented and tested five times, varying the five focal dependent variables (Figure 3)."

12a-i) Imputation techniques to deal with attrition / missing values
Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential

Does your paper address subitem 12a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

YES. Every detail is described in the Multimedia Appendix 1.

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
NO. Not applicable.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem X26-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No direct ethics committee approval was necessary given that the project was granted by the Swiss National Science Foundation and approved by its committees.

x26-ii) Outline informed consent procedures
Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem X26-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
YES.
Quote: "After the registration they had to accept an Informed Consent statement and finally complete a first questionnaire."

X26-iii) Safety and security procedures
Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem X26-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. Not applicable.

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
YES.
Quote: "Patients were randomly assigned to one of the three versions and blinded to the others, using a computer utility that assigned them to a randomly selected experimental condition until the conditions were equally filled."

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No exclusions were necessary.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

Does your paper address subitem 13b-i?
Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. We included an attrition diagram. See Figure 2 in the ms.
14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES.
Quote: "After the questionnaire was completed, the patients could access the website and start the navigation. After five months of access to the site, a second questionnaire was presented and completed."

14a-i) Indicate if critical “secular events” fell into the study period
Indicate if critical “secular events” fell into the study period, e.g., significant changes in Internet resources available or “changes in computer hardware or Internet delivery resources”

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 14a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No specific event occurred.

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
NO. Not applicable.

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. See Table 2 and Table 3 in the ms.

15-i) Report demographics associated with digital divide issues
In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>essential</td>
</tr>
</tbody>
</table>

Does your paper address subitem 15-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. See Table 2.
16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple “denominators” and provide definitions
Report multiple “denominators” and provide definitions: Report N’s (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 16-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. We describe details on effect size on Multimedia Appendix.

16-ii) Primary analysis should be intent-to-treat
Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 16-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. Only primary analysis was performed.

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence
interval)

Does your paper address CONSORT subitem 17a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. We report the estimated effect size for the model tested in Multimedia Appendix 1. We report confidence intervals for each relevant model parameter in Mulimmeda Appendix 2-6.

17a-i) Presentation of process outcomes such as metrics of use and intensity of use
In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

<table>
<thead>
<tr>
<th>subitem not at all important</th>
<th>essential</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

Does your paper address subitem 17a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. We report these metrics and briefly describe them in the ms. We also did a preliminary interaction analysis to check for exposure moderation but found no significant results. For sake of brevity, we did not report the all interaction analysis in the ms.

Quote: "As to the usage of the application, the mean number of visits as recorded by a log file analyzer was 13.27 (SD=26.68). The mean time spend on the website was 4.8 minutes per visit (SD=13.2). These figures suggest that the application was not used very often, but use patterns were similar across experimental conditions. Table 4 reports some usage data related to the main features implemented in the experimental conditions.

In a preliminary phase of the analysis, we introduced the number of visits and the time spent on the application as potential moderators of the relationships implied by the theoretical model. For sake of brevity, we cannot report the whole preliminary evaluation, but the main result was that – at the observed level of usage – no significant moderating effect was found."

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
NO. We only reported general effect size measures (as SEM recommends).

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No other analyses were performed.

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

Does your paper address subitem 18-i? 
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NO. No sub-groups analysis was performed.
19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms., or briefly explain why the item is not applicable/relevant for your study.

NO. No unintended effects were observed.

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical “harm” to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. “Unintended effects” also includes unintended positive effects [2].

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms., or briefly explain why the item is not applicable/relevant for your study.

NO. No privacy breaches or technical problems occurred.

19-ii) Include qualitative feedback from participants or observations from staff/researchers
Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms., or briefly explain why the item is not applicable/relevant for your study.
NO. We did not have any qualitative specific observation.

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)
Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>essential</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 22-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. We summarize the primary results at the beginning of the discussion and in Multimedia Appendix 7.
Quote: "In summary, the presence of interactive elements on our eHealth intervention did not affect knowledge, did not affect patient empowerment in the expected direction (but reduced the empowerment dimension of meaning), and it did not improve the health outcome of perceived fibromyalgia impact. In contrast to other studies, we do not find beneficial effects of functional interactivity. However, knowledge and two dimensions of empowerment...

22-ii) Highlight unanswered new questions, suggest future research
Highlight unanswered new questions, suggest future research.

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>essential</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 22-ii?
YES. We have an entire sub-paragraph in the discussion regarding future directions (too long to be quoted here).

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials
Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem 20-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. We have an entire sub-paragraph in the discussion regarding study limitations (too long to be quoted here).

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations
Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations
Does your paper address subitem 21-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

YES. We have an entire sub-paragraph in the discussion regarding study limitations and generalizability issues (too long to be quoted here).

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting
Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

Does your paper address subitem 21-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

NO. We do not discuss in depth this distinction because our system is used on a regular basis and is not an ad-hoc trial intervention.

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *
24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable. No external fundings were needed. The collaboration of the non-profit League of Rheumatologists was acknowledged in the ms.

Quote: "This study relies on a pre-post test experimental design. Patients were contacted by two means: a list of patients that are members of the Associazione Fibromialgici Svizzeri Sezione Ticino (Ticino Fibromyalgia Patients Association) and patients visiting health professionals (rheumatologists, physiotherapists). "

https://docs.google.com/spreadsheet/viewform?hl=en_US&formkey=dGlKd2Z2Q1INSGQ0...
X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated
In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td>essential</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does your paper address subitem X27-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No conflict of interest.

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

- yes, major changes
- yes, minor changes
- no

What were the most important changes you made as a result of using this checklist?

The checklist is very complete, but to follow every single point is overwhelming. We believe it is a useful instrument but it is unrealistic to assume that every single suggestion can be detailed in a 6000-words manuscript.

The major changes would be:
1. Try to reduce and consolidate mandatory items ("Essential" and "Highly recommended").
2. Please allow users to save the electronic version before submit (so far, one

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript? *

8-10 hours
As a result of using this checklist, do you think your manuscript has improved? *

yes
no
Other: Yes, partly.

Would you like to become involved in the CONSORT EHEALTH group?
This would involve for example becoming involved in participating in a workshop and writing an “Explanation and Elaboration” document

yes
no
Other: Yes, but we would like more info on the workload.

Any other comments or questions on CONSORT EHEALTH

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!